NEJM - Angiotensin–Neprilysin Inhibition

"Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure"

"CONCLUSIONS

LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure. (Funded by Novartis; PARADIGM-HF ClinicalTrials.gov number, NCT01035255.)"

http://www.nejm.org/doi/full/10.1056/NEJMoa1409077?query=featured_home